THE QUANTITATIVE COMPOSITIONS OF MATRIX METALLOPROTEINASES IN BLOOD PLASMA OF DONOR GROUPS WITH VARIOUS TITERS OF ANTI-SARS-COV-2 IGG

Antonina Rachkovska1, Vitaliy Karbovskiy2, Maryna Kalashnikova1

1 1Taras Shevchenko National University of Kyiv, Ukraine

2 2LLC BIOPHARMA-PLASMA, Ukraine

Background. Matrix metalloproteinases (MMPs) play a key role in oxidative stress, circulatory metabolism, and pro- and anti-inflammatory conditions during the progression of SARS-CoV-2 infection. Protease activity dysregulation brought on by the inflammatory response could be connected to complications following COVID-19. Aberrant MMP function may show up in the blood and harm the blood’s proteolytic processes in post-COVID-19 period.

The aim of our research to determine the quantitative levels MMP-1, -2, -3, -8, -9, -10 in blood plasma of donor groups depending on titers of anti-SARS-CoV-2 IgG.

Materials and methods. People who had suffered from COVID-19 agreed to be donors of blood plasma for biotechnological purposes at the "BIOPHARMA-PLASMA" company (Kyiv, Ukraine). Blood plasma was collected from donors who had recovered from COVID-19 3-6 months ago. We had donor groups with anti-SARS-CoV-2 IgG titers (20 donors in each group): 0, 10 ± 3, 55 ± 5, 65 ± 5, 75 ± 5, 85 ± 5, 95 ± 5, 125 ± 5 and 175 ± 5 Index (S/C). Levels of MMP-1, -2, -8, and -9 were determined using an enzyme-linked immunosorbent assay (ELISA).

Results. We established the quantitative amounts of gelatinases (MMP-2, MMP-9) and collagenases (MMP-1, MMP-8) in the blood plasma of donor groups depending on titers of anti-SARS-CoV-2 IgG. Here we have underlined the donor groups with maximum and minimum changes in MMP levels (among donor groups with titers of anti-SARS-CoV-2 IgG ≥ 10 ± 3 Index (S/C)) compared to the reference point (donor groups with titers of anti-SARS-CoV-2 IgG 0 Index (S/C)). The most statistically significant differences are the minimum (125 ± 5 Index (S/C)) and maximum (75 ± 5 Index (S/C)) levels of MMP-2 compared to the reference point; the maximum level of MMP-9 (10 ± 3 Index (S/C)) compared to the reference point; the maximum level of MMP-1 (175 ± 5 Index (S/C)) compared to the reference point; the minimum (10 ± 3 Index (S/C)) and maximum (65 ± 5 Index (S/C)) MMP-8 levels compared to the reference point. The results are presented in Figure 1.

Figure 1
Fig. 1. A) The level of MMP-2 in donor groups with titers of anti-SARS-CoV-2 IgG: 1 – 0; 2– 75 ± 5; 3– 125 ± 5; B) The level of MMP-9 in donor groups with titers of anti-SARS-CoV-2 IgG: 1 – 0; 2 – 10 ± 3;3 – 85 ± 5; C) The level of MMP-1 in donor groups with titers of anti-SARS-CoV-2 IgG: 1 – 0; 2 – 175 ± 5; 3 – 125 ± 5; D) The level of MMP-8 in donor groups with titers of anti-SARS-CoV-2 IgG: 1 – 0; 2 – 65 ± 5; 3 – 10 ± 3.

Conclusion. We confirm the differences between MMP levels of reference point and donor groups with titers of anti-SARS-CoV-2 IgG ≥ 10 ± 3 Index (S/C). We underline that the presence of MMPs in blood plasma at various levels can lead to proteolysis destabilization. It may trigger metabolic dysfunctions and accompanying diseases in the post-COVID-19 period.